SciSparc Expands Patent Portfolio with Psychedelic Compound Combinations

TEL AVIV, Israel, Sept. 23, 2026 /CourierPR/ -- SciSparc Ltd., a clinical-stage pharmaceutical company, announced an expansion of its intellectual property portfolio through a collaboration with Clearmind Medicine Inc. The collaboration has resulted in the filing of three U.S. patent applications covering novel combinations of NeuroThera’s PEA technology with psychedelic compounds such as LSD, ketamine, and ibogaine. These applications are aimed at potential therapeutic uses, including mental health disorders such as depression and post-traumatic stress disorder (PTSD), as well as substance use disorders.

NeuroThera Labs Inc., a subsidiary of SciSparc, is focused on developing novel treatments for central nervous system disorders. The collaboration with Clearmind aims to bring safer and more effective treatments to market for common mental health conditions. The applications build on previously announced intellectual property generated through the partnership, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety, and eating disorders.

The patent applications cover proprietary combinations of PEA technology with LSD, ketamine, and ibogaine. These combinations are being explored for their potential therapeutic applications across a range of indications, including mental health disorders and substance use disorders. SciSparc believes that these combinations may support the development of novel therapeutic approaches for multiple neuropsychiatric and substance use disorder indications.

The continued maturation of the patent portfolio reflects the broader potential applications of NeuroThera’s PEA technology when combined with psychoactive compounds. SciSparc’s subsidiary, NeuroThera, is also engaged in other drug development programs based on THC and/or non-psychoactive CBD, including SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation, and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

SciSparc’s focus on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals is part of its broader strategy. The company is committed to advancing its intellectual property portfolio to support the development of innovative therapeutics. The forward-looking statements in the press release are subject to risks and uncertainties, as detailed in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended.

The press release highlights the ongoing efforts of SciSparc and NeuroThera to expand their intellectual property portfolio and bring new treatments to market. The collaboration with Clearmind continues to advance the development of novel therapeutic approaches, aiming to address the growing needs in the mental health and substance use disorder markets.